Fig. 2From: Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapyPatient disposition of the overall population in the randomized, double-blind, noninferiority phase III trial (chemotherapy cycle 1). aAccording to Hesketh criteria [5]. bSafety population. (From Raftopoulos et al. [19], with permission)Back to article page